<DOC>
	<DOCNO>NCT02457598</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics , preliminary efficacy tirabrutinib ( ONO/GS-4059 ) combination target anti-cancer therapy adult relapse refractory B-cell lymphoproliferative malignancy . This study consist two part : Dose Escalation Dose Expansion . During dose escalation phase , participant sequentially enrol standard 3 + 3 dose escalation study design , receive oral tirabrutinib combine idelalisib entospletinib +/- obinutuzumab . The Dose Expansion Phase enroll additional participant single B-cell lymphoproliferative malignancy disease type evaluate efficacy , safety , tolerability , PK , pharmacodynamics .</brief_summary>
	<brief_title>Dose Escalation Dose Expansion Study Tirabrutinib Combination With Other Targeted Anti-cancer Therapies Adults With B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Diagnosis follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , small lymphocytic lymphoma ( SLL ) , chronic lymphocytic leukemia ( CLL ) ( meet International Workshop Chronic Lymphocytic Leukemia [ IWCLL ] Criteria 2008 ) , mantle cell lymphoma ( MCL ) , Waldenstrom 's macroglobulinemia ( WM ) , nongerminal center Bcell lymphoma ( GCB ) diffuse large Bcell lymphoma ( DLBCL ) document medical record WHO criteria Prior treatment FL , MZL , SLL , MCL , WM ≥ 2 CLL nonGCB DLBCL ≥ 1 chemotherapybased immunotherapybased regimen , transplant eligible either progressive disease ( PD ) response previous treatment For disease Waldenstrom 's macroglobulinemia ( WM ) , presence radiographically measurable presence ≥ 1 lesion measure ≥ 2.0 cm long dimension ( LD ) ≥ 1.0 cm long perpendicular dimension ( LPD ) Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 Platelets ≥ 50 x 10^9/L ; Hb ≥ 8.0 g/dL ; absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L Without transfusion growth factor within 7 day Aspartate transaminase/alanine transaminase ( AST/ALT ) ≤ 2.5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 x ULN Creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) ≥ 60 mL/min Not pregnant Willingness ability comply protocolspecified Pneumocystis jirovecii pneumonia ( PJP ) prophylaxis Key Hepatitis B surface antigen ( HBsAG ) positive hepatitis B core antibody positive Hepatitis C virus ( HCV ) antibody positive History long QT syndrome whose correct QT ( QTc ) interval measure ( Fridericia method ) screen prolong ( &gt; 450 m ) Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>